These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 19571344)
1. Defining the optimal treatment for elderly patients: lessons from real-world data. Meier P; Gurm HS J Invasive Cardiol; 2009 Jul; 21(7):334-5. PubMed ID: 19571344 [No Abstract] [Full Text] [Related]
2. Long-term outcomes comparison of different types of DES in elderly patients from a real-world experience. Sanfilippo A; Cumbo M; Caggegi AM; Monaco S; Bucalo R; Ruperto C; Tamburino C; Ussia GP; Galassi AR; Capranzano P; Capodanno D; Tamburino C J Invasive Cardiol; 2009 Jul; 21(7):330-3. PubMed ID: 19571343 [TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial. Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ J Am Coll Cardiol; 2009 Mar; 53(9):812-3. PubMed ID: 19245976 [No Abstract] [Full Text] [Related]
4. Peeling-off labels mounting evidence for benefit of drug-eluting stents with off-label use. Büttner HJ; Neumann FJ J Am Coll Cardiol; 2007 Nov; 50(21):2037-8. PubMed ID: 18021869 [No Abstract] [Full Text] [Related]
5. Drug-eluting stents for the treatment of acute myocardial infarction: the view to the HORIZONS. Prasad SB; Ahmar W; Malaiapan Y; Meredith IT Heart Lung Circ; 2010 Jan; 19(1):11-8. PubMed ID: 20022808 [TBL] [Abstract][Full Text] [Related]
7. Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents. Yarkoni A; Brodsky A; Sabapathy R; Pershad A Indian Heart J; 2008; 60(3):195-9. PubMed ID: 19240306 [TBL] [Abstract][Full Text] [Related]
8. Left main coronary artery stenting: crossing the Rubicon. Alfonso F J Am Coll Cardiol; 2009 May; 53(19):1769-72. PubMed ID: 19422983 [No Abstract] [Full Text] [Related]
9. Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry. Campo G; Saia F; Percoco G; Manari A; Santarelli A; Vignali L; Varani E; Benassi A; Sangiorgio P; Tarantino F; Magnavacchi P; De Palma R; Guastaroba P; Marzocchi A Int J Cardiol; 2010 Apr; 140(2):154-60. PubMed ID: 19056134 [TBL] [Abstract][Full Text] [Related]
10. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents. Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029 [TBL] [Abstract][Full Text] [Related]
11. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A; J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982 [TBL] [Abstract][Full Text] [Related]
12. Should everolimus-eluting stents be preferred in patients with acute and stable coronary syndromes? Kaul S; Diamond GA JACC Cardiovasc Interv; 2011 Oct; 4(10):1116-8. PubMed ID: 22017937 [No Abstract] [Full Text] [Related]
13. Five-year outcomes of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: are they equally good (or bad)? Cutlip DE Circulation; 2011 Jun; 123(24):2779-81. PubMed ID: 21646497 [No Abstract] [Full Text] [Related]
14. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents. Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063 [TBL] [Abstract][Full Text] [Related]
15. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341 [TBL] [Abstract][Full Text] [Related]
16. Drug-eluting stents: from randomized trials to the real world. Saia F; Degertekin M; Lemos PA; Serruys PW Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571 [TBL] [Abstract][Full Text] [Related]
17. Status of drug-eluting coronary stents. Chodosh A; Korr KS; Burtt D Med Health R I; 2008 Oct; 91(10):309-12, 314. PubMed ID: 19044106 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. Mahmud E; Bromberg-Marin G; Palakodeti V; Ang L; Creanga D; Demaria AN J Am Coll Cardiol; 2008 Jun; 51(25):2385-95. PubMed ID: 18565394 [TBL] [Abstract][Full Text] [Related]
19. Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients. Chiu M; Ko DT; Austin PC; Cohen EA; Velianou JL; Goeree R; Blackhouse G; Tu JV Circ Cardiovasc Qual Outcomes; 2009 Mar; 2(2):96-107. PubMed ID: 20031821 [TBL] [Abstract][Full Text] [Related]
20. Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center. Bose R; Gupta G; Grayburn PA; Laible EA; Kang MJ; Choi JW Am J Cardiol; 2007 Sep; 100(6):949-52. PubMed ID: 17826375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]